, Tracking Stock Market Picks
Enter Symbol:
Rating: MNTA
Buy $15

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) rated to Buy with price target $15 by Brean Capital

Thursday,  Jan 8, 2015  8:25 AM ET by Dave Ficere

Brean Capital rated Momenta
Pharmaceuticals, Inc. (NASDAQ: MNTA) to Buy with price target $15.

Momenta Pharmaceuticals, Inc. is a biotechnology company specializing in the detailed structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs and the discovery of new biological processes. Momenta is also utilizing its ability to sequence sugars to create technology-enabled generic products.

Brean Capital

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy